Abstract
Pathological Gambling (PG) is characterized by “the failure to resist gambling impulses despite severe personal, family or occupational consequences”. PG estimated prevalence ranges between 0.4% and 3.4% within the adult population. PG seems to be more common in patients with Parkinson’s disease (PD) than in the general population. In the past few years, PG has been reported as a side effect of dopamine agonist (DA) therapy used in PD. This association has aroused great interest for the dramatic impact PG has on patients’ quality of life. Management of PG in patients with PD could be demanding. It is based on patient and caregiver education, modification of dopamine replacement therapy, and in some cases psychoactive drug administration. This review describes possible pathogenesis of PG associated with DA therapy, available pharmacological treatments and management approaches that may increase the likelihood of satisfactory treatment outcomes in PD patients.
Keywords: Behavioural therapy, dopamine agonists, impulse control disorders, Parkinson’s disease, pathological gambling, pharmacological therapy, DA therapy, dopamine dysregulation syndrome, OC spectrum disorders, compulsive eating, Mood disorders , impulsivity, Non-ergot dopamine agonists, pharmacologic treatment, Parkinsonism
Current Psychopharmacology
Title:Pathological Gambling in Parkinson’s Disease: An Update on Medical Management
Volume: 1
Author(s): Domenico Pirritano, Massimiliano Plastino, Antonietta Fava, Dario Cristiano, Luca Gallelli, Carmela Colica and Domenico Bosco
Affiliation:
Keywords: Behavioural therapy, dopamine agonists, impulse control disorders, Parkinson’s disease, pathological gambling, pharmacological therapy, DA therapy, dopamine dysregulation syndrome, OC spectrum disorders, compulsive eating, Mood disorders , impulsivity, Non-ergot dopamine agonists, pharmacologic treatment, Parkinsonism
Abstract: Pathological Gambling (PG) is characterized by “the failure to resist gambling impulses despite severe personal, family or occupational consequences”. PG estimated prevalence ranges between 0.4% and 3.4% within the adult population. PG seems to be more common in patients with Parkinson’s disease (PD) than in the general population. In the past few years, PG has been reported as a side effect of dopamine agonist (DA) therapy used in PD. This association has aroused great interest for the dramatic impact PG has on patients’ quality of life. Management of PG in patients with PD could be demanding. It is based on patient and caregiver education, modification of dopamine replacement therapy, and in some cases psychoactive drug administration. This review describes possible pathogenesis of PG associated with DA therapy, available pharmacological treatments and management approaches that may increase the likelihood of satisfactory treatment outcomes in PD patients.
Export Options
About this article
Cite this article as:
Pirritano Domenico, Plastino Massimiliano, Fava Antonietta, Cristiano Dario, Gallelli Luca, Colica Carmela and Bosco Domenico, Pathological Gambling in Parkinson’s Disease: An Update on Medical Management, Current Psychopharmacology 2012; 1 (4) . https://dx.doi.org/10.2174/2211556011201040365
DOI https://dx.doi.org/10.2174/2211556011201040365 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Post-Wortmannin Era: Novel Phosphoinositide 3-Kinase Inhibitors with Potential Therapeutic Applications
Current Enzyme Inhibition The Role of Amitriptyline in the Management of Non-small Cell Lung Cancer
Current Cancer Therapy Reviews Relaxin Receptors - New Drug Targets for Multiple Disease States
Current Drug Targets Revolutionary Impact of Nanodrug Delivery on Neuroscience
Current Neuropharmacology Neurotoxins: Free Radical Mechanisms and Melatonin Protection
Current Neuropharmacology Endocannabinoid Signaling in Midbrain Dopamine Neurons: More than Physiology?
Current Neuropharmacology Expression and Function of Organic Cation and Anion Transporters (SLC22 Family) in the CNS
Current Pharmaceutical Design Redox Sensitivity of Tyrosine Hydroxylase Activity and Expression in Dopaminergic Dysfunction
CNS & Neurological Disorders - Drug Targets HCV-Related Central and Peripheral Nervous System Demyelinating Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Beta-blockers in Children with Duchenne Cardiomyopathy
Reviews on Recent Clinical Trials Physical Inactivity is Liable to the Increased Cardiovascular Risk and Impaired Cognitive Profile
Current Alzheimer Research Multidrug Resistance Associated Proteins as Determining Factors of Pharmacokinetics and Pharmacodynamics of Drugs
Current Drug Metabolism Silencing the Brain May be Better than Stimulating it. The GABA Effect
Current Pharmaceutical Design Fatty Acid-Mediated Inhibition of Metal Binding to the Multi-Metal Site on Serum Albumin: Implications for Cardiovascular Disease
Current Topics in Medicinal Chemistry Molecular Mechanisms Involved in the Control of Neurohypophyseal Hormones Secretion
Current Pharmaceutical Design Artificial Organs: A New Option for Treating Osteoarthritis
Current Drug Delivery Current Biology of MTP: Implications for Selective Inhibition
Current Topics in Medicinal Chemistry Extrasynaptic GABA and Glutamate Receptors in Epilepsy
CNS & Neurological Disorders - Drug Targets The Effect of a Four-Week Balance Training Program on Anticipatory Postural Adjustments in Older Adults: A Pilot Feasibility Study
Current Aging Science Editorial (Thematic Issue: Sleep and Psychiatry)
Current Psychiatry Reviews